Faron, etusivu

releases and publications

Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026

Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML

Faron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING

Regulatory

Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones

Regulatory

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Regulatory

New review published in Immunotherapy highlights the potential for Clever-1 inhibition with bexmarilimab to become the cornerstone of next-generation, multi-indication cancer immunotherapy

Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma

Faron Pharmaceuticals Ltd: PDMR Dealing

Insider Transaction Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Regulatory
PreviousNext
Back to top